Januvia Approval History
- FDA approved: Yes (First approved October 17th, 2006)
- Brand name: Januvia
- Generic name: sitagliptin phosphate
- Company: Merck & Co., Inc.
- Treatment for: Diabetes, Type 2
Januvia (sitagliptin phosphate) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
Development History and FDA Approval Process for Januvia
|Oct 17, 2006||Januvia Merck & Co., Inc. - Treatment for Type 2 Diabetes|
|Feb 15, 2006||Merck Announces FDA Acceptance of New Drug Application for Januvia, the Company's Investigational Medicine for Type 2 Diabetes|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.